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Abstract
Abstract: Lornoxicam is a non-steroidal anti-inflammatory BCS-II class drug, having low solubility and high
permeability. The aim of present investigation was to develop ethosomal gel of lornoxicam, for its transdermal
delivery. The ethosomal formulations were prepared by hot method using phospholipid and ethanol (20% to 40%)
and then evaluated for entrapment efficiency, vesicular size, shape, in-vitro skin permeation, skin retention, drugmembrane component interaction and stability. FT-IR studies revealed no interaction between the drug and
excipients. Transmission electron microscopy (TEM) confirmed the three dimensional nature of ethosomes. The
sonicated ethosomal formulation ET7 was selected for further skin permeation studies as it exhibited highest
percentage of drug entrapment (93.96%) and small particle size (100±3.9 nm). Formulation ET7 containing 2%
w/w phospholipid and 30% alcohol showed highest percentage of drug permeation (74.18%) at the end of 24
hours. The ethosomal vesicles were incorporated in carbopol gel base and its anti-inflammatory efficiency was
compared with the plain lornoxicam gel. The pharmacodynamic studies showed the enhanced anti-inflammatory
activity of ethosomal gel compared to the plain gel formulation. Stability studies carried out at two different
temperatures, showed no significant change in entrapment efficiency of vesicles at the end of 3 months, indicating
that all the formulations were physiochemically stable. The results obtained suggested that the ethosomes could
be an efficient carrier for transdermal delivery of lornoxicam in the treatment of inflammation compared to
plain gel.
Keywords: Lornoxicam, phospholipid, ethanol, ethosomes, sonication.

Introduction
Transdermal drug delivery systems are designed to
deliver a therapeutically effective amount of drug
across a patient’s skin for prolonged period of time1.
In the present scenario, around 40% of the drug
candidates are under clinical evaluation for their
transdermal delivery. Transdermal route offers
several potential advantages over conventional routes
like avoidance of first pass metabolism, predictable
and extended duration of activity, minimizing
undesirable side effects, utility of short half-life
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drugs, improving physiological and pharmacological
response, avoiding the fluctuation in drug levels, inter
and intra patient variations, and most importantly, it
provides patient convince. However, a major problem
in transdermal route is the low penetration rate of
the drug through the outer most layer of skin2. The
non-invasive approaches like usage of permeation
enhancers, vasicular approach, ablation, microneedle
array, ultrasound, iontophoresis, electroporation,
etc. is being used for transdermal drug delivery
of various therapeutic substances3. Among them,
we choose vesicular drug delivery approach. The
application of vesicular system in drug delivery has
changed the definitions of diagnosis and treatment
in different aspects of biomedical field. The vesicular
system such as liposomes, niosomes, ethosomes,
sphinosomes, transferosomes and pharmacosomes
are used to improve the therapeutic index of both

How to cite this article: Acharya A, Ahmed M G, Rao B D, Vinay C H. Ethosomal gel of Lornoxicam. MJPS 2016; 2(1): 13-20.

Manipal Journal of Pharmaceutical Sciences | March 2016 | Volume 2 | Issue 1

Published by Impressions@MAHE, 2022

13

1

Manipal Journal of Pharmaceutical Sciences, Vol. 2 [2022], Iss. 1, Art. 3
Ahmed MG, et al: Ethosomal gel of Lornoxicam

existing and new drug molecules by encapsulating
drug inside vesicular structure in one such system2.
Ethosomes “soft vesicles” represents novel vesicular
carriers for enhanced delivery to or through skin.
The size of ethosomes vesicles can be modulated
from 10 nm to microns. Ethosomes are the modified
forms of liposomes that are high in ethanol content.
The ethosomal system is composed of phospholipid,
ethanol and water. They can penetrate the skin
and enhance compound delivery both to deep skin
strata and systemically. Ethanol present in ethosome
fluidizes both ethosomal lipids and bilayer of the
stratum corneum intercellular lipid. The soft,
malleable vesicles, penetrate the disorganized lipid
bilayers3, 4.
Lornoxicam is a potent non-steroidal antiinflammatory drug (NSAID), used for the variety
of inflammatory conditions such as inflammation,
pain, edema, rheumatoid arthritis. Its half-life is 3 to
5 hours and peak plasma concentration is attained
within 2.5 hours. Lornoxicam is ten times more
potent than other derivatives. The daily dose of
lornoxicam is 8-16 mg taken before meal but dose
above 8 mg should be divided into two or more doses.
The mechanism of action of lornoxicam is primarily
due to inhibition of prostaglandin synthesis through
the inhibition of cyclooxygenase (COX-1 and COX2) enzymes. Like other NSAIDs, common side effect
of lornoxicam is gastrointestinal irritation5, 6.
Lornoxicam satisfied all the criteria required for
transdermal drug delivery. Hence, for the treatment
of inflammation, lornoxicam was selected as model
for its delivery through the skin.
Materials and Methods
materials and reagents used
Lornoxicam was procured from Yarrow Chem
Products, Mumbai, India. Phospholipid was procured
from S.D. Fine Chem. Ltd, Mumbai, India. All other
reagents used were analytical grade.
14
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Animal used
Male albino rats weighing 180-220 g were used
for skin permeation studies and to study antiinflammatory activity.
Ethical approval
The study protocol was approved by Institutional
Animal Ethics Committee, SAC College
of
Pharmacy, BG Nagara-571 448, Karnataka (Reg. no.
SACCP/IAEC/271(b)/2012-13).
Compatibility studies
FT-IR spectrophotometer (Thermo Nicolet FT-IR
system) was used to observe possible interaction
between drug and excipients4.
Preparation of ethosomes
Hot method
Procedure: In hot method, phospholipid was
dispersed in water and dispersion was heated in
a water bath at 40o C until a colloidal solution is
obtained. In a separate vessel, ethanol and propylene
glycol are mixed and heated to 40o C. Once both
mixtures reach 40o C, the organic phase was added to
the aqueous phase. The drug was dissolved in ethanol
due to its hydrophobic property. The drug solution
was then added to the phospholipid dispersion with
continuous stirring on magnetic stirrer (1500 rpm)
for 10 minutes. Finally, the prepared formulations
were stored in refrigerator7.
Preparation of sonicated lornoxicam ethosomes
Ethosomes prepared by the above procedure were
subjected to sonication using ultrasonic bath
sonicator (ICH sonicator, Mumbai) for an hour with
a cycle of 10 minutes8.
Incorporation into Gel
Carbopol 1% w/v was soaked in minimum amount of
water for an hour. 20 ml of ethosomal suspensions
containing lornoxicam (100mg) was added to the
swollen polymer under the continuous stirring at
temperature of 30ºC until homogeneous gels were
achieved. The pH was then adjusted to neutral
using triethanolamine and stirred slowly until a
clear transparent gel was obtained9, 10.
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Table 1: Composition of different un-sonicated ethosomal
formulations
Formulation
code

Phospholipid
(%w/w)

Ethanol
(%w/w)

Propylene
Glycol
(%w/w)

Drug
(%w/w)

Water

ET1

2.0

20

20

0.4

q.s.

ET2

2.0

30

20

0.4

q.s.

ET3

2.0

40

20

0.4

q.s.

ET4

1.0

30

20

0.4

q.s.

ET5

4.0

30

20

0.4

q.s.

Entrapment efficiency: Separation of un-entrapped
drug and evaluation of entrapment efficiency can be
measured by ultracentrifugation. The entrapment
efficiency was calculated using following formula.
Entrapment efficiency = (T– C)/T x 100
Where, ‘T’ is total amount of drug that is detected
both in the supernatant layer and resident layer
and ‘C’ is the amount of drug detected only in the
supernatant11.

ET1, ET2, ET3, ET4 and ET5= formulation code of un-sonicated
ethosomal formulation

In vitro diffusion study using cellophane
membrane

Table 2: Composition of different sonicated ethosomal
formulations

The experiments were conducted in Franz diffusion
cells having donor compartment and a receiver
compartment. A suitable size of pre-treated
cellophane membrane was mounted between
donor and receptor cells of the Franz diffusion
cells (locally fabricated). The receiver contained
15 ml phosphate buffer solution (PBS) at pH 6.8,
was constantly stirred by magnetic stirrer at 100
rpm and was maintained at a temperature of 32 ±
1 ° C throughout the experiments. Formulations
equivalent to 20 mg lornoxicam ethosomal gel was
applied homogenously in the donor compartments;
1ml samples were withdrawn from receiver at
predetermined time intervals over 24 hours and
immediately replenished with an equal volume of
fresh PBS. Samples were assayed for drug content
spectrophotometrically at 376 nm13.

Propylene

Formulation

Phospholipid

Ethanol

code

(%w/w)

(%w/w)

ET6

2.0

20

20

0.4

q.s.

ET7

2.0

30

20

0.4

q.s.

ET8

2.0

40

20

0.4

q.s.

Glycol
(%w/w)

Drug
(%w/w)

Water

ET6, ET7 and ET8= formulation code of sonicated ethosomal
formulation

Preparation of plain drug in gel base
Plain gel of lornoxicam was prepared by similar
method applied for preparation of ethosomal gel. In
this method, required quantity of lornoxicam was
taken and triturated into water miscible gel base.
Final concentration of lornoxicam in formulations
was fixed to 0.4%11.
Evaluation of prepared formulation
Visualization: The initial characterization of the
ethosomal vesicles can be examined by transmission
electron microscopy (TEM). It also visualizes the
lamellar character of ethosomes6.
Vesicle size: The size of the vesicles can be
characterized by optical microscopy with a calibrated
stage micrometer11.
Zeta potential: Particle size of vesicle can be
determined by dynamic light scattering (DLS). The
charge of the ethosomal vesicle is an important
parameter that can influence both vesicular
properties such as stability, skin-vesicle interactions
and its zeta potential can be determined using a
computerized inspection system12.

Kinetic Analysis
The results of in-vitro release profile were plotted in
modes of data treatment as follows:Zero-order Kinetic model – Cumulative percentage
drug released versus time.
First-order Kinetic model – Log cumulative
percentage drug remaining versus time.
Higuchi’s model- Cumulative percentage drug
released versus square root of time.
Korsmeyer equation / Peppa’s model- Log
cumulative percentage drug released versus log
time14.
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In-vitro skin permeation study using rat skin
In-vitro skin permeation studies of ethosomal gel
formulations were carried out on Franz diffusion
cell with an effective diffusion area of 60 mm2 and
15 ml of receptor compartment capacity, using rat
abdominal skin. Firstly, 6 to 8 weeks old male albino
rats weighing 180 to 220g were killed by giving
excess of anesthesia (ether). Skin was excised from
the rat abdominal region, entire hair were removed
with electrical razor and the dermal side of the skin
was wiped with isopropyl alcohol to remove adhering
fat. Then, the skin was washed properly with distilled
water, wrapped in double folded aluminum foil and
finally stored at -20 ° C ±1 until further use. The skin
was brought to room temperature and treated with
0.5 M NaOH solution for 1-1.5 hours. Pre-treated
skin was cut into appropriate size and mounted
between the two half of Franz diffusion cell where
dermis faced towards the receptor compartment
and the stratum corneum faced towards donor
compartment. Initially, receptor compartment was
filled with phosphate buffer (pH 6.8) while donor
compartment was kept empty. The temperature of
the apparatus was maintained 32±0.5 ° C throughout
the study period. The receiver fluid was stirred with
magnetic rotor at a speed of 100rpm. The whole
receiver fluid was replaced with fresh buffer solution
after every 20 minutes to stabilize the skin. It was
found that the receiver fluid showed a negligible UV
absorption after 3 hours indicating the complete
stabilization of the skin membrane. The formulation
equivalent to 20 mg of lornoxicam was applied
on the skin in donor compartment. Samples were
withdrawn at predetermined time intervals over 24
hours, and suitably diluted with phosphate buffer to
analyze the drug content6.

of carrageenan in saline (0.1 ml) into plantar site of
right hind paw and the percentage inhibition of paw
edema was measured by plethysmometer (IITC) 15.
Stability studies
Stability study was carried out by storing the
ethosomal formulations at two different temperatures
4o C and 25±2 o C. The drug content was estimated for
3 months to identify any change in the entrapment
efficiency of ethosomal formulation16.
RESULTS
Compatibility Study
Physical mixture of drug and polymer was
characterized by FT-IR spectral analysis for any
physical as well as chemical alteration of the drug
characteristics. Results of FT-IR spectroscopy are
shown in Table 3 and Figures 1 and 2.
Table 3: Interpretations of IR-spectrum
Functional
group

Wave number (cm-1)
Pure Drug

Drug and physical mixture

OH

3437

NH

3101

3141

CH-Ar

3067

3021

C=N

1649

1735

C=O

1595

1576

C=C

1425

1437

S=O

1039

1091

C-Cl

704

749

3393

In-vivo anti-inflammatory activity
Carrageenan induced paw edema method was used to
compare the anti-inflammatory activity of plain gel
and ethosomal gel. The animals were divided into
three groups, each group having four animals. First
group served as normal control receiving normal gel
containing saline. Second group received lornoxicam
plain gel, and third group received lornoxicam
ethosomal gel. 30 min after formulation application
(0.5 g), rats of both treated groups were challenged
by a subcutaneous injection of a 1% (w/v) solution
16
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Figure 1: IR Spectrum of Lornoxicam

Figure 2: FT-IR spectra of drug and physical mixture
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Visualization:

ET6

Visual characterization of the vesicles was examined
by transmission electron microscopy (Tecnai 200
with CCD, Philips Instruments, Holland). In TEM
image analysis, both the sonicated and un-sonicated
ethosomes are having spherical bilayer vesicles with
a smooth surface (figure 3 A, B).

ET7

ET8

A

Figure 4: Vesicular size distribution of sonication formulation
ET6, ET7 and ET8

Comparison of zeta potential:
B
Figure 3: Transmission electron microscopy (TEM) of
(i) un-sonicated ethosomes, (ii) sonicated ethosomes

Vesicles size analysis:
The vesicle size and diameter of sonicated
ethosomes was found in the range of 13.9 nm
and 30.7 nm respectively, whereas un-sonicated
formulation exhibited vesicle size 33.7 nm and 53.0
nm average diameter. Vesicular size distribution of
the sonicated product was measured with special
software developed by “ZETASIZER NS 300 HSA”.

Zeta potential analysis was done by using Malvern
Zetasizer (Malvern Instrument Ltd., Model S.,
Ver.5.03, Malvern, UK) in order to determine the
surface charge of the vesicles. The zeta potential of
un-sonicated formulation ET2 (-48.23±1.9mV) was
high when compared with sonicated formulation
ET7 (-45.35±2.9mV).
Entrapment efficiency
The ability of vesicles to entrap lornoxicam was
investigated by ultracentrifugation method (Remi
Elektrotech, Limited, Vasai, India, centrifuge).
Ultracentrifugation was the method used to separate
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vesicles containing drug and free drug and to find out
the entrapment efficiency. The sonicated ethosomes
formulation ET7 containing 2% phospholipids and
30% ethanol showed highest entrapment efficiency
i.e. 70.25% (Figure 5).

formulation. According to the in-vitro drug release
profiles, the best release in un-sonicated ethosomes
was shown by ET2 i.e., 91.32% drug release. In case
of sonicated formulations best release was exhibited
by formulation ET7 i.e., 93.96% drug release at the
end of 24 hours.
In-vitro skin permeation study
In-vitro skin permeation was conducted for plain
lornoxicam gel and ethosomal gel (ET2 and ET7)
for a period of 24 hours using rat skin. It has been
observed that the ethosomal system showed higher
permeation compared to plain gels (Figure 8).

Figure 5: Comparative entrapment efficiency of ethosomes
before and after sonication

Figure 6: Comperative drug release profile of un-sonicated
ethosomal formulation

Figure 7: Comperative drug release profile of sonicated
ethosomal formulation

In-vitro drug release studies:
For in-vitro drug release studies, cellophane
membrane having MW cut-off range 12,000-14,000
was used. This type of cellophane membrane only
allows the diffusion of drug molecule in solution form
while it does not allow lipid vesicles to pass through
it. Therefore, to diffuse the entrapped drug through
cellophane membrane, first it should release from
the vesicles to surrounding liquid medium. In this
present study, a drug release study was performed
for both sonicated and un-sonicated ethosomal
18
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Figure 8: Comperative skin permeation study of three different
formulation

Drug release kinetics
The release obeyed zero, first order kinetics, the
results of this investigation showed high correlation
coefficient among the formulation for mixed order
release and the probable release mechanism was
initial diffusion. The value of release exponent (n)
was found to be a function of the polymer used
and the physicochemical properties of the drug
molecule itself and the ‘n’ values was found to be
in the range of 0.410 to 0.5463 followed with nonFickian release.

Figure 9: Comparison of in-vivo anti-inflammatory activity
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Comparison of in-vivo anti-inflammatory activity
Carrageenan induced paw edema method was used
to compare the anti-inflammatory activity of plain
lornoxicam gel and ethosomal gel using albino
rats (Figure 9). Results of the anti‐inflammatory
studies showed that after 4 hours of gel application,
ethosomal gel formulation had comparatively higher
inhibition of inflammation (64.2%) than plain gel
formulation (40.48%) with lesser time for onset of
action.
Stability studies
Ethosomal formulations ET2 and ET7 were kept
for 3- month stability studies for any change in
appearance or color for a period of 3 months.
Discussion
FT-IR studies showed there was no interference
of the functional group peaks of the lornoxicam
in ethosomal formulation, indicating they were
chemically compatible. There was no change in
functional group peaks (OH, C-Cl, S=O,-C-H, C=N,
N-H, C=O, CH-Ar) of lornoxicam in all the IRspectra, hence compatible. A size of un-sonicated
vesicles was comparatively larger than the sonicated
ethosomal vesicles and was of multilamellar and
giant type. This might be because the drug that was
not entrapped properly in vesicles remains free after
sonication, which resulted in smooth and smaller
size.
Decrease in vesicles size of sonicated ethosomes
might be due to the stress exhibited by the ethosomal
vesicles after its sonication resulting in removal of
un-entrapped drug as well as phospholipids. Among
all formulations, formulation ET1 containing 20%
ethanol exhibited vesicle diameter of 53.0 nm and
up on increasing concentration of ethanol (from
20%-40%) vesicle size gradually decreases from 53.0
nm to 33.7 nm. Ethanol significantly reduces vesicle
membrane thickness, as it provides the softness for
vesicle membrane and result in interpenetration of
hydrocarbon chain (ethanol) in the vesicular lipid
bilayer. Furthermore, ethanol imparts a net negative
charge to the ethosomal system and confers it some
degree of steric stabilization that may finally lead to
a reduction in vesicular size. Zeta potential values
are high for ethosomal formulations. A high zeta-

potential value (>-30 mV) is beneficial to vesicles
physical stability as it prevents aggregation between
vesicles owing to electrostatic repulsion.
Sonicated ethosomes ET7 exhibited highest
percentage of entrapment compared to un-sonicated
ethosomal formulation; this might be due to the
possible reduction in vesicle size and also due to
presence of optimum concentration ethanol, which
probably has greater ability to retain lornoxicam in
ethosomal core.
The amount of drug release for sonicated
formulation was comparatively higher than
un-sonicated formulation. High percentage of
drug release by the sonicated formulation might
be because these formulations have smaller vesicle
sizes and highest percentage of drug loading
capacity. In-vitro drug release results also suggested
that the ethosomal formulations of lornoxicam
provide a sustained delivery of drug over a period
of 24 hour through cellophane membrane. Drug
permeation for ethosomal formulation was also
higher for ethosomal gel compared to plain gel,
this might be due to fact that ethanol present in the
ethosomal formulation provides soft and flexible
characteristics to the vesicles, which allow them
to more easily penetrate into deeper layers of the
skin. Finally, results suggested that in ethosomal
formulation there was some kind of synergistic
mechanism between ethanol, vesicles, and skin
lipids, which make it more permeable through skin.
Among ethosomal gels, sonicated ethosomal gel
showed higher percentage of permeation 74.18 %
(ET7), which was slightly higher than un-sonicated
ethosomal gel 65.45% (ET2). Higher permeation rate
of drug from sonicated ethosomes might be smaller
size of vesicles compared to un-sonicated vesicle.
There was no change in appearance in ethosomal
formulations throughout the period of study.
Even significant changes were not observed under
the magnified view, hence prepared formulation
was stable. Thus, ethosomal formulation may be
considered as a good choice to improve absorption
of the anti‐inflammatory drug like lornoxicam.
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Conclusion
In the present study, lornoxicam entrapped
ethosomal gel for transdermal drug delivery
was prepared by using various concentrations
of phospholipids and ethanol. The prepared
formulation showed good entrapment efficiency,
particle size and drug release. The result advocates
the superiority of ethosomal formulation over the
plain gel formulation with respect to skin permeation
and anti-inflammatory activity. In conclusion, it can
be suggested that ethosomes could be superior drug
carrier for topical delivery of lornoxicam in the
treatment of inflammation.
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